News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subscribe To Our Newsletter & Stay Updated
